Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.54 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | INSR | P06213 | 3/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620572 | 1.00 | ALK (0.54) | ALKEGFRPLK1INSRIGF1R | |
| SCHEMBL24620633 | 0.94 | ALK (0.56) | ALKEGFRPLK1INSRIGF1R | |
| SCHEMBL30833015 | 0.94 | ALK (0.56) | ALKEGFRPLK1INSRIGF1R | |
| SCHEMBL30833018 | 0.94 | ALK (0.61) | ALKEGFR | |
| SCHEMBL24620268 | 0.94 | ALK (0.61) | ALKEGFR | |
| SCHEMBL24620237 | 0.92 | ALK (0.54) | ALKEGFRPLK1INSRIGF1R | |
| SCHEMBL29791543 | 0.92 | ALK (0.54) | ALKEGFRPLK1INSRIGF1R | |
| SCHEMBL29791375 | 0.92 | ALK (0.54) | ALKEGFRPLK1INSRIGF1R | |
| SCHEMBL27175302 | 0.92 | ALK (0.54) | ALKEGFRPLK1INSRIGF1R | |
| SCHEMBL24620234 | 0.92 | ALK (0.56) | ALKEGFRPLK1INSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | claimed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| EP-4277902-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | ALK 430/4885EGFR 1022/4885PLK1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.